pomalidomide has been researched along with Leukemia, Myeloid, Acute in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben Amara, A; Benyamine, A; Castanier, C; Castellano, R; Collette, Y; Fauriat, C; Fournié, JJ; Goubard, A; Granjeaud, S; Le Roy, A; Mege, JL; Olive, D; Orlanducci, F; Pont, F; Prébet, T; Riccardi, F; Vey, N | 1 |
| Foster, MC; Zeidner, JF | 1 |
| Lentzsch, S; Pan, B | 1 |
2 review(s) available for pomalidomide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2017 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
1 other study(ies) available for pomalidomide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; CD56 Antigen; Cells, Cultured; Cytotoxicity, Immunologic; Genes, MHC Class I; Humans; Immunologic Factors; K562 Cells; Killer Cells, Natural; Lenalidomide; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Monitoring, Immunologic; Natural Cytotoxicity Triggering Receptor 3; Thalidomide; Xenograft Model Antitumor Assays | 2018 |